10-K/A: cbdMD Files Amendment to 10-K to Include Omitted Information on Directors and Executive Compensation

cbdMD, Inc. filed an amendment to its annual report on Form 10-K to include information previously omitted regarding directors, executive officers, and executive compensation.

Summary

• cbdMD, Inc. filed Amendment No. 1 on Form 10-K/A to amend its Annual Report on Form 10-K for the fiscal year ended September 30, 2024.
• The amendment includes information required by Part III of the original filing, which was omitted because the company no longer intends to file a definitive proxy statement involving the election of directors within 120 days of the fiscal year end.
• Part IV of the original filing is also amended to add new certifications by the co-principal executive officers and the principal financial officer.
• The company's common stock outstanding as of December 16, 2024, was 5,539,124 shares.
• As of January 20, 2025, the company had 6,262,833 shares of common stock issued and outstanding.
• T. Ronan Kennedy serves as the Chief Executive Officer and Chief Financial Officer.
• Bradley Whitford serves as the Chief Accounting Officer, Treasurer, and Secretary.
• Scott G. Stephen is the Chairman of the Board of Directors.
• Bakari Sellers, William F. Raines, III, and Dr. Sibyl Swift serve as directors.
• Dr. Swift served as Chief Science Officer & VP Regulatory Affairs until August 2024 and remains a consultant.
• The annual retainer for independent directors is $35,000, plus a stock award of 4,000 shares and an option grant of 2,000 shares.
• Audit fees for fiscal 2024 were $231,653, audit-related fees were $27,289, and tax fees were $39,200.
• The total fees for the independent registered public accounting firm for fiscal 2024 were $298,142.

Sentiment

Score: 7

Explanation: The document is primarily factual and related to regulatory compliance. The sentiment is neutral to slightly positive as it reflects adherence to regulations and standard corporate governance practices.

Positives

• The company is adhering to SEC regulations by filing the necessary amendments to its 10-K report.
• The board of directors includes members with diverse backgrounds and experience.
• The company has established corporate governance policies, including a Code of Business Conduct and an Insider Trading Policy.
• The Compensation, Corporate Governance and Nominating Committee is focused on providing competitive compensation to attract and retain talented executives.
• The company has equity compensation plans in place to incentivize employees, officers, directors, and consultants.

Negatives

• The need to file an amendment suggests an initial oversight in the original 10-K filing.
• The company no longer intends to file a definitive proxy statement which involves the election of directors within 120 days of the end of our fiscal year ended September 30, 2024.

Risks

• The company faces risks related to its ability to continue as a going concern.
• The company faces risks related to increasing its customer base.
• The company faces risks related to diversifying its sales.
• The company faces risks related to improving profitability.
• The company identifies operational, regulatory, strategic, reputation, credit, interest rate, and liquidity risks.

Industry Context

This filing is a routine amendment to a standard SEC filing, ensuring compliance with regulatory requirements for publicly traded companies in any industry.

Comparison to Industry Standards

• The director compensation structure, including retainers, stock awards, and option grants, is generally in line with compensation practices at similar-sized publicly traded companies.
• Audit fee levels are within a reasonable range for companies of comparable size and complexity, based on industry benchmarks.
• Executive compensation packages, including base salaries and potential bonuses, appear to be structured to attract and retain qualified personnel, aligning with industry norms.

Management Changes

Related Party Transactions

• Dr. Sibyl Swift, a board member, received a salary of $240,000 for fiscal 2024 as Chief Science Officer and VP Regulatory Affairs and is now a consultant with a monthly retainer of $8,000.

Stakeholder Impact

• The amendment ensures transparency and provides stakeholders with complete information regarding the company's directors, executive officers, and compensation practices.
• Adherence to SEC regulations helps maintain investor confidence.

Key Dates

Keywords

cbdMD, 10-K/A, Amendment, Directors, Executive Compensation, Corporate Governance, Financial Statements, Audit Fees, Stock Options, SEC Filing